Accueil   Diary - News   All news Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas

Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas

  • First trial to test the ultra-rapid insulin BioChaperone Lispro with automated insulin delivery

 

  • Using the insulin-only configuration of the iLet Bionic Pancreas system, this trial will investigate effect of different pharmacokinetic characteristics of insulin aspart, insulin lispro, and ultra-rapid BioChaperone Lispro on glycemic control

 

Lyon, France, January 3rd 2019 – 6:00 pm CET - ADOCIA (Euronext Paris: FR0011184241 – ADOC), a biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of approved proteins, announced today the first home-use trial to test Adocia’s BioChaperone® Lispro in Beta Bionics autonomous insulin delivery system, the iLetTM.

 


Investigators at the Massachusetts General Hospital Diabetes Research Center have designed and will perform the study, which is funded by the Leona M. and Harry B. Helmsley Charitable Trust.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree